EpiCast Report: Glaucoma - Epidemiology Forecast to 2026

EpiCast Report: Glaucoma - Epidemiology Forecast to 2026

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eyes optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), or secondary glaucoma (SG), though other less common types exist. OAG and ACG can be classified as primary (primary open-angle glaucoma [POAG] or primary angle-closure glaucoma [PACG], respectively) or SG, depending on the cause.

To forecast the total prevalent cases of POAG, PACG, NTG, PPG, and SG in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases of PPG from primary market research and authentic secondary sources. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

In the 7MM, the total prevalent cases of POAG will increase from 7,224,135 cases in 2016 to 8,549,547 cases in 2026, at an Annual Growth Rate (AGR) of 1.83%. In the 7MM, the total prevalent cases of PACG will increase from 2,644,012 cases in 2016 to 3,124,740 cases in 2026, at an AGR of 1.82%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

Scope

- The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG), segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of glaucoma clinical types normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG.
- The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Glaucoma EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
- Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
- Understand the population of glaucoma clinical types NTG, PPG, and SG.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Related Reports 8
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global and Historical Trends 10
3.4 Forecast Methodology 12
3.4.1 Sources 13
3.4.2 Forecast Assumptions and Methods 18
3.4.3 Total Prevalent Cases of POAG 18
3.4.4 Total Prevalent Cases of PACG 20
3.4.5 Total Prevalent Cases of NTG and PPG 22
3.4.6 Total Prevalent Cases of SG 22
3.4.7 Diagnosed Prevalent Cases 23
3.4.8 Diagnosed Incident Cases of Acute PACG 24
3.5 Epidemiological Forecast for Glaucoma (2016-2026) 24
3.5.1 Total Prevalent Cases of POAG 24
3.5.2 Age-Specific Total Prevalent Cases of POAG 26
3.5.3 Sex-Specific Total Prevalent Cases of POAG 27
3.5.4 Diagnosed Prevalent Cases of POAG 27
3.5.5 Total Prevalent Cases of PACG 28
3.5.6 Age-Specific Total Prevalent Cases of PACG 29
3.5.7 Sex-Specific Total Prevalent Cases of PACG 30
3.5.8 Diagnosed Prevalent Cases of PACG 30
3.5.9 Total Prevalent Cases of NTG 31
3.5.10 Diagnosed Prevalent Cases of NTG 32
3.5.11 Total Prevalent Cases of PPG 33
3.5.12 Diagnosed Prevalent Cases of PPG 33
3.5.13 Total Prevalent Cases of SG 34
3.5.14 Diagnosed Prevalent Cases of SG 35
3.5.15 Diagnosed Incident Cases of Acute PACG 35
3.6 Discussion 36
3.6.1 Epidemiological Forecast Insight 36
3.6.2 Limitations of the Analysis 37
3.6.3 Strengths of the Analysis 37
4 Appendix 38
4.1 Bibliography 38
4.2 High-Prescribing Physician Survey 40
4.3 About the Authors 40
4.3.1 Epidemiologist 40
4.3.2 Reviewers 40
4.3.3 Global Director of Therapy Analysis and Epidemiology 41
4.3.4 Global Head and EVP of Healthcare Operations and Strategy 42
4.4 About GlobalData 43
4.5 Contact Us 43
4.6 Disclaimer 44

List Of Tables

Table 1: Risk Factors and Comorbidities for Glaucoma 10
Table 2: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 25
Table 3: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 28
Table 4: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 28
Table 5: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 31
Table 6: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 31
Table 7: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 32
Table 8: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 33
Table 9: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 34
Table 10: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 34
Table 11: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 35
Table 12: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages 40 Years, N, Selected Years 2016-2026 36
Table 13: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017 40

List Of Figures

Figure 1: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages 40 Years, 2016 and 2026 6
Figure 2: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages 40 Years, 2016 and 2026 7
Figure 3: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages 40 Years, 2016 11
Figure 4: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages 40 Years, 2016 12
Figure 5: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG 13
Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG 14
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG 15
Figure 8: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG 16
Figure 9: 7MM, Sources Used to Forecast Total Prevalent Cases of SG 17
Figure 10: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG 17
Figure 11: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages 40 Years, N, 2016 26
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages 40 Years, N, 2016 27
Figure 13: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages 40 Years, N, 2016 29
Figure 14: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages 40 Years, N, 2016 30

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available